COMPARATIVE EFFECTS OF ATENOLOL VERSUS CELIPROLOL ON SERUM-LIPIDS AND BLOOD-PRESSURE IN HYPERLIPIDEMIC AND HYPERTENSIVE SUBJECTS

被引:8
作者
DUJOVNE, CA [1 ]
EFF, J [1 ]
FERRARO, L [1 ]
GOLDSTEIN, RJ [1 ]
GOTTO, AM [1 ]
HALL, WD [1 ]
HARRIS, WS [1 ]
HELD, SJ [1 ]
HERD, A [1 ]
HUNNINGHAKE, DB [1 ]
JOHNSON, BF [1 ]
SZTERN, MI [1 ]
机构
[1] UNIV KANSAS,LIPID & ARTERIOSCLEROSIS PREVENT CLIN,LAWRENCE,KS 66045
关键词
D O I
10.1016/0002-9149(93)90981-H
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Antihypertensive drugs may affect serum lipoprotein levels in mixed populations but data in hyperlipidemic patients are scanty. Atenolol versus celiprolol effects on serum lipoproteins were compared in 159 hyperlipoproteinemic hypertensive patients. This was a randomized, double-blind, parallel-group, positive-controlled multicenter trial with centralized lipoprotein laboratory and diet constancy monitoring. Blood pressure reduction and serum lipoprotein and apoprotein levels were monitored for 3 months. Both drugs reduced systolic and diastolic blood pressures. Atenolol had greater effects than celiprolol on diastolic pressure, but effects on systolic blood pressure were not different. Patients receiving atenolol had lower serum high-density lipoprotein cholesterol levels and higher low-density lipoprotein/high-density lipoprotein cholesterol ratios, whereas patients treated with celiprolol showed no contrasting changes. These differences in lipoprotein levels between drug treatment groups were statistically significant at weeks 9 and 12. The difference between drug treatments was also significant if the values of the 9- and 12-week visits were averaged. Patients taking atenolol had statistically significantly higher serum levels of total cholesterol, triglycerides and apoprotein B at 9 weeks. These divergent directional changes were consistent throughout and statistically significantly different between drugs.
引用
收藏
页码:1131 / 1136
页数:6
相关论文
共 18 条
[1]
CONNOR SL, 1986, LANCET, V1, P1229
[2]
SERUM-LIPIDS IN NORMOLIPIDEMICS AND HYPERLIPIDEMICS AFTER METHYLDOPA AND PROPRANOLOL [J].
DUJOVNE, CA ;
DECOURSEY, S ;
KREHBIEL, P ;
JACKSON, B ;
CHERNOFF, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (02) :157-162
[3]
ANTIHYPERTENSIVE AGENTS, SERUM-LIPOPROTEINS AND GLUCOSE-METABOLISM [J].
FERRARI, P ;
ROSMAN, J ;
WEIDMANN, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 67 (10) :B26-B35
[4]
HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[5]
GRIMM RH, 1988, CHOICES CARDIOL, V2, P208
[6]
HARRIS WS, 1988, ARTERIOSCLEROSIS, V8, pA633
[7]
EFFECTS OF A LOW SATURATED FAT, LOW CHOLESTEROL FISH OIL SUPPLEMENT IN HYPERTRIGLYCERIDEMIC PATIENTS - A PLACEBO-CONTROLLED TRIAL [J].
HARRIS, WS ;
DUJOVNE, CA ;
ZUCKER, M ;
JOHNSON, B .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (06) :465-470
[8]
JACKSON B, 1986, J AM DIET ASSOC, V86, P1531
[9]
JOHNSON BF, 1982, J CARDIOVASC PHARM, V4, pS213
[10]
THE RELEVANCE OF PLASMA-LIPID CHANGES WITH CARDIOVASCULAR DRUG-THERAPY [J].
JOHNSON, BF ;
DANYLCHUK, MA .
MEDICAL CLINICS OF NORTH AMERICA, 1989, 73 (02) :449-473